It is likely that new mutation acquisition from sustained exposure to BBN after tamoxifen induced expression of the VP16;Pparg transgene may be a driver of these changes, as bladder cancer has one of the highest tumor mutational burden. The gene discussed is PPARG; the disease is urinary bladder cancer.